Javier Mixco

Javier Mixco
Javier Mixco, M.D.,  has experience helping clients with patent-related matters in the medical device, health device, life science, pharmaceutical, and chemical technology fields. He has experience counseling clients in making strategic plans for their intellectual property portfolios both domestically and internationally. Javier’s medical degree has been invaluable when helping clients bridge the gap between science and patent law.  While in law school, Javier served as the Editor-in-Chief of the Utah Law Review. He also served as a judicial extern for Justice Matthew B. Durrant on the Utah Supreme Court, and the Honorable Judge Dee Benson with the U.S. District Court for the District of Utah.

Educational Background
S.J. Quinney College of Law, University of Utah, J.D., 2012; Order of the Coif; Editor-in-Chief, Utah Law Review
Duke University School of Medicine, M.D., 2007
Harvard University, B.A., cum laude Biological Anthropology, 2000

Bar Admissions
U.S. District Court for the District of Utah
U.S. Patent & Trademark Office


Medical Device, Pharmaceutical, and Life Science Industries
Javier has experience in the medical device industry, in particular helping clients innovate endotracheal tubes, stents, venous filters, connectors, grafts, and catheters. Javier has also worked with clients that are developing new vascular access and endovascular technologies, stents and stent delivery systems, grafts, inflation systems, drug delivery systems, embolics, and orthopedic surgical technologies and techniques, vascular filters, needle systems, and antimicrobial and thromboresistant polymer coatings. 

In the pharmaceutical and life science industry, clients have benefited from Javier’s experience with various disease states and pathogens including fragile X mental retardation, melanoma, peripheral neuropathies, human respiratory syncytial virus, poliovirus, adenovirus, influenza virus H3N2, Bordetella pertussis, diabetes mellitus, and insulin resistance generally. In addition, Javier has specific experience prosecuting patents involving RNAi technology, nanoparticle mediated delivery systems, pharmacological treatments, biomarker diagnostics, gene therapies, fusion proteins, molecular glycosylation patterns, mitochondrial function, immunoglobulins including monoclonal and single domain camelid VHH antibodies, small-drug compound selection technologies, G-protein mediated binding, muscarinic acetylcholine receptor binding agents, opioid receptor binding agents, and antimicrobials including antihelminthics and nematocides.

Chemical, Agricultural, and Other Industries
Javier has experience with plant biomass enhancement, drought resistance, and productivity, and three-dimensional microenvironments for cell culture. He also has worked with clients that are innovating a wide range of mechanical and chemical systems and devices including mining equipment, wagering game devices, photoactive devices, semiconductors, LEDs, and miniature fluid atomizers.

Supremes Rule on Bilski. K. Chahine, J. Mixco. Nature Biotechnology 28, 767 (2010)
Selective gamma-aminobutyric acid type A receptor antagonism reverses isoflurane ischemic neuroprotection. Elsersy H, Mixco J, Sheng H, Pearlstein RD, Warner DS. Anesthesiology. 2006 Jul; 105(1):81-90. PMID: 16809998
Intraischemic nitrous oxide alters neither neurologic nor histologic outcome: a comparison with dizocilpine. Yokoo N, Sheng H, Mixco J, Homi HM, Pearlstein RD, Warner DS. Anesth Analg. 2004 Sep; 99(3):896-903. PMID: 15333428
Severe hypotension is not essential for isoflurane neuroprotection against forebrain ischemia in mice. Homi HM, Mixco JM, Sheng H, Grocott HP, Pearlstein RD, Warner DS. Anesthesiology. 2003 Nov; 99(5):1145-51. PMID: 14576552

© 1999- 2019 Smith and Hopen, P.A.  SMITH & HOPEN® and logo are federally registered trademarks.  Legal